Literature DB >> 25560533

Colorectal cancer in 2014: progress in defining first-line and maintenance therapies.

Joleen M Hubbard1, Axel Grothey1.   

Abstract

The results of several clinical trials in metastatic colorectal cancer presented in 2014 will influence clinical practice. These findings include definitive data from phase III trials comparing bevacizumab and cetuximab-based therapy in the first-line, studies elucidating the value of maintenance therapy after induction treatment, and data on new agents in this disease.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25560533     DOI： 10.1038/nrclinonc.2014.233

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  2 in total

1.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

Authors:  Volker Heinemann; Ludwig Fischer von Weikersthal; Thomas Decker; Alexander Kiani; Ursula Vehling-Kaiser; Salah-Eddin Al-Batran; Tobias Heintges; Christian Lerchenmüller; Christoph Kahl; Gernot Seipelt; Frank Kullmann; Martina Stauch; Werner Scheithauer; Jörg Hielscher; Michael Scholz; Sebastian Müller; Hartmut Link; Norbert Niederle; Andreas Rost; Heinz-Gert Höffkes; Markus Moehler; Reinhard U Lindig; Dominik P Modest; Lisa Rossius; Thomas Kirchner; Andreas Jung; Sebastian Stintzing
Journal:  Lancet Oncol       Date:  2014-07-31       Impact factor: 41.316

2.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321
  2 in total
  18 in total

Review 1.  Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma.

Authors:  Bhaskar Bhardwaj; Swaroop Revannasiddaiah; Himanshu Bhardwaj; Sree Balusu; Ali Shwaiki
Journal:  Ann Transl Med       Date:  2016-02

2.  Gastrointestinal cancer: Rationale for metronomic chemotherapy in phase III trials.

Authors:  Robert S Kerbel; Axel Grothey
Journal:  Nat Rev Clin Oncol       Date:  2015-05-12       Impact factor: 66.675

3.  Autophagy inhibition sensitizes WYE-354-induced anti-colon cancer activity in vitro and in vivo.

Authors:  Lijun Wang; Yun-Rong Zhu; Shaowei Wang; Song Zhao
Journal:  Tumour Biol       Date:  2016-03-28

4.  Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.

Authors:  Huang Zhijun; Wang Shusheng; Min Han; Li Jianping; Qin Li-Sen; Li Dechun
Journal:  Tumour Biol       Date:  2016-02-01

5.  Sex, Race, and Age Disparities in the Improvement of Survival for Gastrointestinal Cancer over Time.

Authors:  Jue-Feng Wan; Li-Feng Yang; Yun-Zhu Shen; Hui-Xun Jia; Ji Zhu; Gui-Chao Li; Zhen Zhang
Journal:  Sci Rep       Date:  2016-07-13       Impact factor: 4.379

6.  The preclinical analysis of TW-37 as a potential anti-colorectal cancer cell agent.

Authors:  Shun Lei; Yao Ding; Yun Fu; Shuang Wu; Xiong Xie; Cancan Wang; Houjie Liang
Journal:  PLoS One       Date:  2017-10-24       Impact factor: 3.240

7.  Silencing protein kinase C ζ by microRNA-25-5p activates AMPK signaling and inhibits colorectal cancer cell proliferation.

Authors:  Shihu Zhang; Yiyang Zhang; Qing Cheng; Zhaoqun Ma; Guanwen Gong; Zhengming Deng; Kun Xu; Gaoyuan Wang; Yousong Wei; Xiaoping Zou
Journal:  Oncotarget       Date:  2017-06-27

Review 8.  Use of Jianpi Jiedu Herbs in Patients with Advanced Colorectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Shaofan Zhang; Li Shi; Dan Mao; Weijun Peng; Chenxia Sheng; Chenchen Ding; Fengxia Lin; Caiyun Lei; Sifang Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2018-01-29       Impact factor: 2.629

Review 9.  Current Landscape in Organic Nanosized Materials Advances for Improved Management of Colorectal Cancer Patients.

Authors:  Octav Ginghină; Ariana Hudiță; Cătălin Zaharia; Aristidis Tsatsakis; Yaroslav Mezhuev; Marieta Costache; Bianca Gălățeanu
Journal:  Materials (Basel)       Date:  2021-05-08       Impact factor: 3.623

10.  LASP1-S100A11 axis promotes colorectal cancer aggressiveness by modulating TGFβ/Smad signaling.

Authors:  Ya Niu; Ziyun Shao; Hui Wang; Jiaqi Yang; Feifei Zhang; Yuhao Luo; Lijun Xu; Yanqing Ding; Liang Zhao
Journal:  Sci Rep       Date:  2016-05-16       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.